The Motley Fool

Millennials: 2 Expensive Growth Stocks Still Worth Buying

Image source: Getty Images

Millennials have one of the greatest advantages when it comes to investing: time. The power of long-term compounding is as profound as it is difficult to fathom. Many Canadians likely underestimate the wealth-creating effects of a TFSA portfolio invested in the common shares of wonderful businesses. In a prior piece, we did the math and determined that many millennials who keep at it with TFSA contributions and investments are not only millionaires in the making; they could be worth far more by the time they hit retirement age.

The longer the investment horizon, the more pronounced the effects of compounding will be. With taxes taken out of the equation, with a TFSA, millennials have a distinct edge that can help level the playing field with prior generations. There’s no question that millennials have been dealt a brutal hand, having suffered through the 2008 Great Financial Crisis and 2020 COVID-19 Crisis early on in their careers. With disciplined investments in a TFSA, not all hope is lost on the cohort that’s had more than their fair share of challenges.

Millennials should seek to take on more risk for more reward!

Millennials who’ve taken the self-guided investment route ought to be applauded, as delegating the task of managing wealth comes at a very hefty cost. By taking exorbitant portfolio management fees and taxes via investing in a TFSA, millennials can tilt not only retire by 60, but they could retire far sooner. To maximize the effects of long-term TFSA compounding, millennials should seek to take on more risk with growth stocks capable of greater long-term appreciation. Consider shares of early-stage growth companies such as Kinaxis (TSX:KXS) and Docebo (TSX:DCBO).

Kinaxis: Down but not out

Kinaxis is a software developer that provides solutions that help untangle the mess that is the supply chain. Amid the pandemic and partial lockdowns, vast supply/demand imbalances are the “new normal,” and such disruption calls for an increased demand in products that can help ease the pains involved with taming such a complicated beast.

The stock has been in a downward spiral for most of the month, retreating viciously following news of two effective vaccines that had the potential to end the pandemic as soon as next year. While Kinaxis is one of many stocks that has been a beneficiary of the pandemic, the loss of pandemic tailwinds, I believe, will be less pronounced. Why? The pandemic hasn’t just caused a pull-forward in demand for its product; I believe the firm has experienced an acceleration to its business. With greater recognition among prospective clients, I think Kinaxis will rise out of this pandemic strong, even without pandemic tailwinds.

Docebo: A winner that keeps on winning

After a turbulent past few months, high-flying Learning Management System (LMS) software developer Docebo (TSX:DCBO) is back at it, surging to a new all-time high of $60. The stock has appreciated an absurd 460% since its lows and March. Although the white-hot stock is ridiculously expensive, I still think millennial investors should get some skin in the game today, because I don’t think the name is about to slow down anytime soon, even with the pandemic’s end in sight.

Docebo won some impressive clients during the pandemic. With the work-from-anywhere movement likely to continue well after the pandemic ends, the demand, I believe, for LMS offerings will continue to be robust. The company is just starting to make a name for itself, and with a world of growth opportunities ahead of it, I’d say now is the time to pick up shares before they have a chance to get away.

Shares of Docebo trade at around 22 times sales at the time of writing. That’s expensive! But it could easily get more expensive, given the firm’s growth potential. Also, I have a feeling that Docebo’s incredible win streak isn’t about to end anytime soon. The early-stage growth stock is just getting started.

If you're looking for opportunities in this uncertain market, I'd encourage you to consider the following:

Just Released! 5 Stocks Under $49 (FREE REPORT)

Motley Fool Canada's market-beating team has just released a brand-new FREE report revealing 5 "dirt cheap" stocks that you can buy today for under $49 a share.
Our team thinks these 5 stocks are critically undervalued, but more importantly, could potentially make Canadian investors who act quickly a fortune.
Don't miss out! Simply click the link below to grab your free copy and discover all 5 of these stocks now.

Claim your FREE 5-stock report now!

Fool contributor Joey Frenette has no position in any of the stocks mentioned. The Motley Fool recommends KINAXIS INC.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss an important event.

Iain Butler and the Stock Advisor Canada team only publish their new “buy alerts” twice a month, and only to an exclusively small group.

This is your chance to get in early on what could prove to be very special investment advice.

Enter your email address below to get started now, and join the other thousands of Canadians who have already signed up for their chance to get the market-beating advice from Stock Advisor Canada.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.